Brieflands

History

The company was first founded by Seyyed M. Miri and Seyed-M Alavian as an editorial group in a Medical Institute in 2007 to publish its medical journal. After three years of experience, the number of journals increased to 5 journals, and the company launched its first form of business as a VOF (collaboration) professional STM company in Heerlen, the Netherlands, which was called "Kowsarmedical Publishing." Respecting the publishing services (from submission to publishing), especially an in-house "Journal Management System," our journals increased to more than 60 STM journals between 2010 and 2019. Since 2022, "Brieflands" is the new brand name that acts as a "Science, Technical, Medical Publisher" that publishes more than 50 journals with the services provided by 97 expert employees in three different branches.

Business Profile

Brieflands is a Registered Trademark with record number 1454012.
Brieflands has been registered as a General partnership (Vennootschap onder firma) company in the Chamber of Commerce (Kamer van Koophandel) of the Netherlands since 2010.
- KvK number: 89235444.
- BTW (VAT) number: NL864918896B01 (check online at VIES )
- RSIN: 864918896
Nedmedica is our related company which is specialized in Author Services.
Our former branding name was Kowsarmedical Publishing (2010-2021).

Communities in Brieflands

Select a community to browse its collections.

Recent Submissions

Comparison of the Effects of Audible Guided Imagery and Self-selected Instrumental Music on Comfort and the Well-Being Index in Hemodialysis Patients: A Randomized Controlled Trial
(Brieflands, 2026-12-31)
Omidreza Siavash
;
Masoumeh Bagheri-Nesami
;
Abolfazl Hosseinnataj
;
Ravanbakhsh Esmaeili
;
Fatemeh Espahbodi
Background: Comfort and well-being are fundamental to the psychological health and life satisfaction of patients undergoing hemodialysis. Objectives: This study aimed to compare the effects of audible guided imagery (AGI) and self-selected instrumental music (SSIM) on comfort and well-being indices among patients undergoing hemodialysis. Methods: In this randomized controlled trial, 90 hemodialysis patients were allocated to 3 groups (n = 30 each): AGI, SSIM, and control, using sex-stratified block randomization. The interventions lasted 20 minutes per session, 3 times per week for 4 weeks, while the control group received routine care. Comfort and well-being were assessed at baseline and at the ends of weeks 2 and 4 using Kolcaba's Hospice Comfort Questionnaire and the World Health Organization Five Well-Being Index (WHO-5). Data were analyzed using SPSS version 22 with chi-square, Kruskal-Wallis, and Mann-Whitney tests and generalized estimating equations regression. Results: Baseline comfort and well-being scores did not differ significantly among the groups. However, both intervention groups showed significant improvements by the second and fourth weeks (P < 0.05). In the SSIM group, comfort scores increased from a baseline of 93.77 ± 13.81 to 116.90 ± 8.31 at week 2, reaching 121.60 ± 7.53 by week 4. The AGI group showed a similar trajectory, with comfort scores rising from 93.53 ± 13.08 at baseline to 117.60 ± 10.47 (week 2) and 121.90 ± 7.33 (week 4). Regarding well-being, the control group exhibited a slight downward trend over time (from 57.33 ± 23.36 to 50.27 ± 18.66). In contrast, the SSIM group showed a significant increase in well-being (from 64.80 ± 21.49 to 86.93 ± 9.45), as did the AGI group (from 65.87 ± 18.64 to 87.73 ± 10.02). The regression analysis showed that both intervention groups achieved significantly higher comfort and well-being scores over time than those in the control group. The models included the main effects of time and group and were adjusted for age, education, and diabetes. Conclusions: No statistically significant difference was detected between the two interventions in this sample; however, both SSIM and AGI can serve as effective nonpharmacological interventions to enhance comfort and subjective well-being in hemodialysis patients after 4 weeks.
Morphology, Viability, and Expression of Cardiac Markers in Human Cardiomyocytes After Exposure to Methamphetamine
(Brieflands, 2026-12-31)
Hossein Kargar Jahromi
;
Khatere Roozbehi
;
Faezeh Ebrahimi-Zadeh
;
Vida Mirzaei
;
Fatemeh Parsaei
Background: Methamphetamine (METH), a highly addictive amphetamine derivative, is associated with severe cardiovascular complications, including cardiomyopathy. However, its precise effects on human cardiomyocytes (HCM) remain poorly understood. Objectives: This study aimed to evaluate the biological activity of HCM, including viability and cardiac-related marker expression, after exposure to METH. Methods: Cultured HCM were treated with 0.6 mM METH or phosphate-buffered saline vehicle. Cell morphology was assessed by inverted microscopy on days 1, 3, and 6. Viability was measured using the trypan blue exclusion method over 8 days. Expression of GATA-binding protein 4 (GATA4) and creatine kinase transcripts was measured by real-time polymerase chain reaction (PCR) on days 1, 3, and 6, with β-actin as the endogenous control. Experiments were performed in 3 biological replicates, each assessed in technical triplicate. Independent-samples t tests, analysis of variance (ANOVA), and post hoc tests were used for statistical comparisons between the METH-treated and vehicle-treated groups. A P < 0.05 was considered statistically significant. Results: Unlike vehicle-treated cells, METH-treated HCM appeared unhealthy, with long, thin cytoplasmic processes on days 3 and 6. The number of viable cells increased transiently by day 4 but declined sharply by day 6 compared with vehicle-treated cells. GATA4 expression peaked significantly on day 1 (4.53 ± 0.74; 95% CI, 2.69 - 6.37; P = 0.011), decreased by day 3 (1.17 ± 1.43; 95% CI, 0.00 - 4.72), and was downregulated by day 6 (0.10 ± 0.23; 95% CI, 0.00 - 0.67) compared with the vehicle-treated group. Creatine kinase transcript expression showed a similar, statistically nonsignificant trend. Expression increased to 1.81 ± 0.71 (95% CI, 0.05 - 3.57) on day 1 and then was 1.47 ± 1.46 (95% CI, 0.00 - 5.10) on day 3. By day 6, expression had dropped sharply to 0.11 ± 0.38 (95% CI, 0.00 - 1.05). Conclusions: Methamphetamine induces morphological changes, increases cell number, and dynamically alters the expression of cardiac-related markers in HCM, possibly reflecting early stress followed by dysfunction. These findings highlight changes in cardiomyocyte biological activity after METH exposure that may adversely affect cellular function. This study also demonstrates the potential of HCM models for investigating cardiomyopathy associated with exogenous substances.
From Stein-Leventhal to PMOS: Is It Time to Move Beyond the Ovary?
(Brieflands, 2027-01-31)
Fahimeh Ramezani Tehrani
;
Samira Behboudi-Gandevani
;
Fereidoun Azizi
;
Fahimeh Ramezani Tehrani [0000-0002-4609-065X]
;
Samira Behboudi-Gandevani [0000-0003-3526-640X]
This article does not have an abstract.
Clinical and Laboratory Determinants of Elevated Transaminases in COVID-19 Patients
(Brieflands, 2026-09-30)
Behzad Bijani
;
Ladan Borjalizadeh
;
Abbas Allami
;
Monirsadat Mirzadeh
;
Mohammad Mahdi Farhani
Background: Liver enzyme elevation is a common but serious extrapulmonary manifestation of COVID-19 and has been associated with increased disease severity and adverse patient outcomes. Objectives: This study aimed to identify independent clinical and laboratory factors associated with elevated transaminases among hospitalized patients with COVID-19. Methods: We conducted a retrospective cross-sectional analysis at Bu-Ali Sina Hospital in Qazvin, Iran, using data from 266 patients with confirmed COVID-19. Consecutive eligible records were selected using an outcome-based case-control sampling structure, with 133 patients in each group. Patients were categorized as having elevated or normal transaminase levels based on admission measurements. Demographic, clinical, and laboratory parameters were extracted for all participants. Logistic regression using the forward conditional method was performed to identify independent factors associated with elevated transaminase levels. Results: Statistically significant factors associated with elevated transaminases were male sex (odds ratio [OR], 3.21; 95% confidence interval [CI], 1.73 - 5.95; P < 0.001), high-acuity Emergency Severity Index (ESI) levels 1 - 2 (OR, 3.18; 95% CI, 1.47 - 6.89; P = 0.003), lymphopenia (OR per 100 cells/μL decrease, 0.90; 95% CI, 0.84 - 0.97; P = 0.004), and elevated erythrocyte sedimentation rate (ESR; OR per unit increase, 1.024; 95% CI, 1.006 - 1.042; P = 0.008). Elevated transaminases were also significantly associated with higher odds of intensive care unit (ICU) admission (adjusted OR, 2.7; 95% CI, 1.6 - 4.6; P < 0.001) and in-hospital mortality (OR, 2.5; 95% CI, 1.3 - 4.8; P = 0.005). Conclusions: Routine early monitoring of liver enzymes in high-risk patients, particularly males with high-acuity ESI levels 1 - 2, lymphopenia, and elevated ESR, may guide management and potentially improve prognosis. However, these associations do not establish causality because the study was retrospective and cross-sectional, with an outcome-based case-control structure.
Assessment of HCV-RNA Testing Results and Genotype Distribution Among Anti-HCV-Positive Patients in Aksu Prefecture, Xinjiang, China: A Retrospective Hospital-Based Study
(Brieflands, 2026-12-31)
Hangchuan Mei
;
Gang Niu
;
Junsheng Ma
;
Hui Song
Background: Hepatitis C virus (HCV) is a major cause of chronic liver disease worldwide. However, local data on HCV RNA positivity and genotype distribution among anti-HCV-positive patients in Aksu Prefecture remain limited. Objectives: To describe HCV-RNA positivity and genotype distribution among anti-HCV-positive patients tested at a regional hospital in Aksu Prefecture and to evaluate demographic and geographic associations with HCV-RNA positivity. Methods: This retrospective hospital-based study included 4,735 independent anti-HCV-positive patients with valid HCV-RNA results at the Third People’s Hospital of Aksu Prefecture in 2024. Proportions were reported with Wilson 95% confidence intervals (CIs). A multivariable logistic regression model including sex, age group, and region was fitted to the individual-level analytical subset from eight regions (n = 3,842). Results: HCV RNA was detected in 1,361 of 4,735 anti-HCV-positive patients (28.74%; 95% CI, 27.47% - 30.05%). In the eight-region individual-level subset, 1,283 of 3,842 patients were HCV RNA-positive (33.39%; 95% CI, 31.92% - 34.90%). Male sex was associated with higher adjusted odds of HCV RNA positivity than female sex (adjusted odds ratio [aOR], 2.22; 95% CI, 1.91 - 2.57). Patients aged 31 - 40 years also had higher adjusted odds of HCV RNA positivity than those aged ≥ 61 years (aOR, 1.75; 95% CI, 1.41 - 2.16). Genotype 1b was the most frequent (41.59%), followed by 3a (26.60%), 2a (19.54%), and 3b (11.32%). Conclusions: HCV-RNA positivity and genotype distribution varied across demographic and geographic strata within this hospital-tested, anti-HCV-positive cohort. These estimates do not represent population-level prevalence in Aksu Prefecture.